Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04323423
Other study ID # Glycemic variability & SB
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date December 1, 2025
Est. completion date December 1, 2025

Study information

Verified date March 2024
Source Western University, Canada
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Rationale: Older adults spend the majority of their time in sedentary behaviours (SB). High amounts of SB have been correlated with reduced cognitive performance. Long periods of time spent sitting results in excessive glycemic variability, potentially contributing to cognitive decline. Reducing/replacing SB with short intermittent bouts of light physical activity have shown positive effects on glycemic variability. Thus, interrupting prolonged sitting with bouts of light physical activity may regulate blood glucose and thus mitigate cognitive decline. Purpose: This study intends to investigate the appropriate interval frequency of post-prandial SB reduction, by light physical activity needed to optimize total and incremental area under the curve for glucose response in overweight older adults at risk for glucose intolerance with mild cognitive impairment in both lab and free-living environments. Second, this study aims to investigate the acute impact of reducing SB on glycemic variability and its relationship with cognition. Hypothesis: First, there will be a dose-dependent response of more frequent interruptions of SB (more frequent intervals of light physical activity) with better glycemic control. Second, reducing SB will result in less glycemic variability, which will translate into better levels of cognitive performance. Methods: Generalized linear mixed models with random intercepts will be used to evaluate the differential effects of the experimental conditions on the selected outcomes.


Description:

This study will be a randomized crossover trial and reported in accordance with CONSORT guidelines. The study will involve a total of three seven-day conditions (2 experimental and 1 control) with a three-week washout period in-between to minimize practice effects for a total intervention period of nine weeks (see figure 1). Each condition will consist of one day supervised in the laboratory followed by six at-home days, following lab protocol as closely as possible. Participants will be referred to the study by their physician. Interested participants will be asked to contact the researcher by email or phone call. Interested Participants will be invited into the lab for a familiarization session. They will be instructed to avoid caffeine, alcohol and MVPA for 48 hours prior to this session. During this session the following information will be obtained; - Written informed consent - Height using a stadiometer and weight using a standard beam scale - Demographics questionnaire (education, ethnicity, family background, comorbidities) - Physical Activity Readiness Questionnaire (PARQ+) (Bredin, Gledhill, Jamnik, & Warburton, 2013) - Resting blood pressure- will be measured once on each arm and then twice on the left arm with an automated BP monitor The participants will be educated/familiarized on the following; - Cognitive assessments - Cambridge Neuropsychological Test Automated Battery (CANTAB) - Fitting with an inclinometer (activPAL4) Participants will be visited at their home ~72hrs prior to each condition to be fitted with the CGM and ActivPal. They will also be instructed to avoid caffeine, alcohol and MVPA for 48 hours prior to each of the three conditions. Dinner will be consumed between 7:00 and 9:00 pm, allowing for a 10 hour fast prior to the experimental condition the next morning. All participants will be instructed to arrive at the laboratory (with minimal activity during commute) at approximately 7:00 am. Upon arrival, participants will be asked to use the washroom and then rest for 30 minutes preceding a blood pressure measurement and first cognitive assessment. The participants will undergo the CANTAB cognitive assessments (at ~7:30 am) before meal consumption. A standardized breakfast meal will be consumed at 8:00 am, followed by lunch at 12:00 pm and dinner at 5:00 pm. Participants will be allotted 20 minutes for full meal consumption. The CANTAB cognitive assessments will then be re-administered at approximately 7:30 pm. Participants will be supervised throughout the conditions to ensure adherence to the protocols and will be permitted to watch DVDs, read books, magazines, newspapers, talk and/or work on a laptop computer. However, what they do during the first condition will be documented and then replicated for the remaining experimental conditions. Intensity of the bout intervals will be kept to an RPE of 6-9 using the Borg RPE scale. Once the 12- hour laboratory component is complete, participants will be sent home (still wearing the CGM and activPAL) with the intension of replicating the laboratory-based protocol after each meal in their own free-living environment. Participants will track their mealtimes by sending photos to the researcher before consumption during the 6 at home days. The researcher will then go to the participants house on the last day (day 7) of each condition to re-administer the CANTAB cognitive assessments and collect the CGM, and activPal. There will then be a 3-week washout period, followed by replication of protocol for the remaining two conditions.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 1, 2025
Est. primary completion date December 1, 2025
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - Age = 65 years - Have a caregiver that works with you at least 20 hours a week (needs to be present for the familiarization session (explained below) and drop-off and pick-up from lab sessions) - Diagnosis of diabetes by a healthcare provider (e.g. family doctor). - Diagnosis of MCI by a healthcare provider - Self-report being physically inactive (not meeting the current PA guidelines of 150 min MVPA/week) - Self-report being sedentary- (defined as self-reported sedentary time = 7 h/day) - Able to walk one block without an assistive device - Own a smartphone with unlimited outgoing text messages and access to internet connection. The smartphone must be either iphone 7 (with iOS of 12.2 or higher) or Android operating system 5 or higher to allow for Libre View mobile application compatibility. - Able to read, write and understand English Exclusion Criteria: - Currently smoke - Depression (Geriatric Depression Score short-form > 6 (GDS)) (Yesavage, Brink, Rose, & et al, 1983). - Medication: hypoglycemics; antilipidemics; antidepressants; beta blockers; anti-anxiety agents - Peri-menopausal or menopausal women (must be post-menopausal) - Excessive alcohol consumption (> 8 points on the Alcohol Use Disorders Identification Test) - Uncontrolled hypertension (measured systolic > 140 mmHg or diastolic > 90 mmHg)

Study Design


Intervention

Behavioral:
interrupting sedentary behaviour with light physical activity
replacing sitting with light walking bouts at different frequencies/durations

Locations

Country Name City State
Canada The University of Western Ontario London Ontario

Sponsors (1)

Lead Sponsor Collaborator
Western University, Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Glycemic Variability to investigate the appropriate interval frequency of post-prandial SB reduction, by light physical activity needed to optimize total and incremental area under the curve for glucose response in overweight older adults at risk for glucose intolerance with mild cognitive impairment in both lab and free-living environments. 1-7 days
Secondary Cognition CANTAB will be used to measure change in cognitive function. This is a computerized battery of neuropsychological tests utilizing touch sensitive screen technology that has been shown to be highly sensitive and a precise measure of cognitive function, correlated to neural networks (CANTAB, 2017). The following three cognitive domains were selected for testing; attention and psychomotor function (Motor Screening Task (MOT) and Rapid Visual Information Processing (RVP)), memory (Delayed Matching to Sample (DMS)) and executive function (Intra-Extra Dimensional Set Shift (IED)) 1-7 days
See also
  Status Clinical Trial Phase
Completed NCT04513106 - Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial N/A
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Active, not recruiting NCT03167840 - Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment N/A
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Not yet recruiting NCT05041790 - A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment Phase 4
Recruiting NCT04121156 - High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment N/A
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Completed NCT02774083 - Cognitive Training Using Feuerstein Instrumental Enrichment N/A
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Enrolling by invitation NCT06023446 - Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
Completed NCT04567745 - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers Phase 1
Recruiting NCT05579236 - Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
Completed NCT03583879 - Using Gait Robotics to Improve Symptoms of Parkinson's Disease N/A
Terminated NCT02503501 - Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease Phase 2
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Active, not recruiting NCT05204940 - Longitudinal Observational Biomarker Study
Recruiting NCT02663531 - Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease N/A
Recruiting NCT06150352 - Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
Recruiting NCT03507192 - Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia. N/A